Risultati per: Terapia antipiastrinica e anticoagulante per pazienti con angina instabile o NSTEMI

I dati del progetto Pascnet coordinato dalla Cattolica di Milano

90% di quelli estremamente pretermine sottoposto a cure dolorose

IncontraDonna, grazie al teatro benefici mentali e relazionali

Studio del Policlinico Federico II

L’impianto di un nuovo stent evita l’intervento a cuore aperto

Potranno effettuare in un’unica giornata tutti gli esami

Test avviati negli Usa. A Ferrara trattata una paziente, tra i primi centri in Europa

Oncologi, la preservazione della fertilità tra le nuove problematiche

Annals of Internal Medicine, Ahead of Print.

Attese dei letti rallentano accessi:12 minuti in più per ogni malato

Ricoverato il 60%, il 13,5 in terapia intensiva, mortalità 10,6%

Questore e suoi collaboratori all’ospedale pediatrico di Trieste

Introduction
Ischaemic heart disease (IHD) is a pathological process characterised by a blockage or non-obstructive accumulation of atherosclerotic plaques in the epicardial arteries. Percutaneous coronary intervention (PCI) is widely used in clinical practice to treat IHD. However, angina post PCI (APPCI) impairs quality of life and portends a worse prognosis. Hence, an effective and safe treatment option remains an urgent need for patients with APPCI. In recent years, there has been an increasing body of clinical trials regarding the use of acupuncture for the prevention and treatment of APPCI, and the results have indicated it might be a promising therapeutic intervention. However, to our knowledge, the potential benefits of acupuncture for the prevention and treatment of APPCI to justify either their recommendation or their clinical role have not been evaluated.

Methods and analysis
PubMed, Embase, Cochrane Library, Web of Science Core Collection, Chinese Biomedical Database, Chinese National Knowledge Infrastructure, Wanfang Database and VIP Database will be searched from inception to 8 June 2024 without language restrictions. Two investigators will independently screen studies, extract data, assess the risk of bias from randomised controlled trials (RCTs) and assess the risk of bias. The third reviewer will arbitrate any disagreements. Data synthesis and analysis will be conducted using the RevMan V.5.4 software. Subgroup analyses, sensitivity analysis, meta-regression and bias reporting assessments will be performed if necessary and appropriate. Finally, the quality of evidence from RCTs will be assessed using the Grading of Recommendations Assessment, Development, and Evaluation System tool.

Ethics and dissemination
Ethical approval is unnecessary since no private or confidential patient data will be included. The systematic review will be published in peer-reviewed journals.

PROSPERO registration number
CRD42024562116.